

<b>NCT ID</b>	NCT05879822
<b>Title</b>	A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-05-30
<b>Location</b>	Brazil China Georgia Greece Hungary New Zealand Romania South Africa Turkey
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	INCB099280
<b>Tags</b>	MSI-H/ MMRd
<hr/>	
<b>NCT ID</b>	NCT05865535
<b>Title</b>	A Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-05-19
<b>Location</b>	California, United States Connecticut, United States Florida, United States Nebraska, United States New Jersey, United States New York, United States Oregon, United States South Carolina, United States Tennessee, United States Texas, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT05838768
<b>Title</b>	Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-05-03

<b>Location</b>	California, United States
	Massachusetts, United States
	New York, United States
	Texas, United States
	Belgium
	China
	France
	Germany
	Israel
	Italy
	Japan
	Norway
	Singapore
	South Korea
	Spain
	Sweden
	Taiwan
	United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	HRO761, Irinotecan
<b>Tags</b>	MSI-H/ MMRd
<hr/>	
<b>NCT ID</b>	NCT05799443
<b>Title</b>	Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-04-05
<b>Location</b>	
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Not yet recruiting
<b>Drugs</b>	cetuximab, Irinotecan Hydrochloride, Tislelizumab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT05798533
<b>Title</b>	Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-04-04
<b>Location</b>	China
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Cyclophosphamide, Fludarabine, Interleukin-2
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT05785325
<b>Title</b>	RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-03-27
<b>Location</b>	China
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting

<b>Drugs</b>	RC48-ADC plus Bevacizumab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT05784688
<b>Title</b>	Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2023-03-27
<b>Location</b>	Texas, United States Washington, United States Korea, Republic of
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	TU2218 + Pembrolizumab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT05783089
<b>Title</b>	MSLN-targeted CAR-T Cells in Solid Tumors.
<b>Phase</b>	Phase 1
<b>Date Added</b>	2023-03-24
<b>Location</b>	
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Not yet recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT05771181
<b>Title</b>	Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-03-16
<b>Location</b>	China
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Fruquintinib, Tislelizumab, Vitamin E
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT05770102
<b>Title</b>	DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
<b>Phase</b>	Phase 2, Phase 3
<b>Date Added</b>	2023-03-15
<b>Location</b>	United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	Atezolizumab
<b>Tags</b>	MSI-H/ MMRd